Combination of azelastine fluticasone, effective against allergic rhinitis
new YORK (Reuters Health) – the review of three trials randomized and controlled reveals that an experimental formula that combines azelastine and fluticasone (MP29-02) is more effective that the administration of one or another drug as therapy intranasal rhinitis allergic seasonal (SAR) to. “This provides for the first time strong clinical evidence “ that antihistamines and intranasal corticosteroids they are complementary in the pathogenesis pharmacological effects “ of allergic rhinitis”, writes in Journal of Allergy and Clinical Immunology the team of Dr. Warner Carr of Allergy and Asthma Associates of Southern California. The international team carried out three tests of 14 days each one with 3,398 patients with RAE moderate to severe during various allergy seasons. After a first period of seven days, the participants autoadministraron MP29-02 (137 mcg of azelastine/50 mcg of fluticasone propionate) or 137 mcg of azelastine or 50 mcg of fluticasone or a placebo. Made it every 12 hours, in each nostril with a spray. The authors combined the results of trials in a meta-analysis, whose main result would be the reduction of total Nasal symptoms, according to a scale of 0-24 points, during the treatment period. The reduction in the dose of MP29-02 (-5.7) was significantly higher than that of fluticasone (- 5.1), azelastine (- 4.4) or placebo (- 3). “MP29-02 combination took 30 minutes to begin to “ Act. “The clinical benefits arose...
Read More